Business
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with
About this update from Vivani Medical, Inc.
[{"type":"text","content":"\nVivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing\n\n\nVivani previously announced sham-implant adjusted preclinical weight loss of 20%, which is comparable to the weight loss produced from the semaglutide (active ingredient in Ozempic®/Wegovy®) injection control arm in the same study\n\n\nClinical development of Vivani’s exenatide implant in overweight and obese patients as part of the Company’s NPM-115 program remains on track to commence in the fourth quarter of 2024\n\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nVivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today reported positive preclinical liver fat results with its exenatide implant.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904740218/en/Liver fat % area for exenatide implant vs sham implant 12 weeks after a single administration. Liver fat % area is calculated using Oil Red O (ORO) staining. Values are mean ± SE. (Graphic: Business Wire)\n“The reduction in liver fat observed preclinically with our miniature, subdermal exenatide implant, provides further support that the NanoPortal™ implant technology continues to hold great potential as a highly differentiated treatment option for the treatment of obesity and chronic weight management as well as related metabolic disorders,” said Adam Mendelsohn, Ph.D., Vivani President and Chief Executive Officer. “While the currently marketed GLP-1 based drugs have made profound improvements in the treatment of chronic diseases, including obesity and chronic weight management, significant barriers to optimal patient outcomes persist due to medication non-adherence and poor tolerability. We remain committed to the development of our portfolio of innovative, miniature, GLP-1 implant candidates and their potential to improve real-world patient outcomes by improving medication adherence. In addition, we believe that our implant’s minimally fluctuating release profile combined with avoiding inevitable drug fluctuations that result from poor adherence may have the potential to improve treatment tolerability, a primary com...